Oncology Dataset
Oncology Cohort Collection
Consented, de-identified oncology biobank cohort data with genomic, clinical, and biomarker modalities. Designed with HIPAA Safe Harbor de-identification standards, with full consent chain documentation for licensing.
Request This DatasetDataset specifications
This collection covers solid tumor and hematologic malignancy cohorts, with matched WES/WGS genomic calls, clinical phenotyping, serum biomarker panels, and longitudinal follow-up records up to 48 months. All records are de-identified per HIPAA Safe Harbor method, QC-validated, and consent-verified before catalog inclusion. Suitable for biomarker discovery, tumor mutation burden analysis, and response prediction model development.
Available modalities
- Genomic (WES/WGS)
- Clinical phenotyping
- Serum biomarkers
- Longitudinal follow-up
Common research indications
- Solid tumors (mixed histology)
- Hematologic malignancies
- Biomarker validation cohorts
Dataset metadata
Sample range800–3,200 subjects
De-identificationHIPAA Safe Harbor (18 identifiers)
Consent modelBroad consent, re-consent available
Primary modalitiesGenomic / Clinical / Biomarker
Follow-up durationUp to 48 months
FormatVCF, FHIR R4, CSV
Last updatedQ4 2025
Ready to access this dataset?
Submit a data brief and our team will confirm availability, cohort fit, and delivery timeline.